ACADIA PHARMACEUTICALS INC (ACAD) Forecast, Price Target & Analyst Ratings

NASDAQ:ACAD • US0042251084

23.31 USD
+0.81 (+3.6%)
Last: Mar 4, 2026, 02:24 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACADIA PHARMACEUTICALS INC (ACAD).

Forecast Snapshot

Consensus Price Target

Price Target
$32.16
+ 37.95% Upside

Next Earnings Forecast

Earnings Estimate
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$0.08
Revenue Estimate288.67M

ChartMill Buy Consensus

Rating
78.52%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
$32.16
Upside
+ 37.95%
From current price of $23.31 to mean target of $32.16, Based on 27 analyst forecasts
Low
$17.17
Median
$32.64
High
$42.00

Price Target Revisions

1 Month
4.17%
3 Months
9.34%

Price Target Summary

27 analysts have analysed ACAD and the average price target is 32.16 USD. This implies a price increase of 37.95% is expected in the next year compared to the current price of 23.31.
The average price target has been revised upward by 9.34% in the past 3 months.
 → Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ACAD Current Analyst RatingACAD Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

ACAD Historical Analyst RatingsACAD Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20 25

Analyst Ratings Consensus

ChartMill Buy Consensus
78.52%
ACAD was analyzed by 27 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about ACAD.
In the previous month the buy percentage consensus was at a similar level.
ACAD was analyzed by 27 analysts, which is quite many. So the average rating should be quite meaningful.
 → Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-02-26CitizensMaintains Market Outperform -> Market Outperform
2026-02-26TD CowenMaintains Buy -> Buy
2026-02-26RBC CapitalMaintains Outperform -> Outperform
2026-02-26StifelMaintains Hold -> Hold
2026-02-24Wolfe ResearchInitiate Outperform
2026-02-23MizuhoUpgrade Neutral -> Outperform
2026-02-06OppenheimerMaintains Perform -> Perform
2026-02-03CitizensReiterate Market Outperform -> Market Outperform
2026-02-03RBC CapitalMaintains Outperform -> Outperform
2026-02-03HC Wainwright & Co.Reiterate Buy -> Buy
2026-01-06UBSMaintains Buy -> Buy
2026-01-06CitigroupMaintains Buy -> Buy
2025-12-15HC Wainwright & Co.Maintains Buy -> Buy
2025-12-11StifelMaintains Hold -> Hold
2025-12-02MizuhoMaintains Neutral -> Neutral
2025-11-17JP MorganMaintains Overweight -> Overweight
2025-11-06NeedhamMaintains Buy -> Buy
2025-11-06RBC CapitalMaintains Outperform -> Outperform
2025-10-21CitigroupInitiate Buy
2025-09-29JP MorganMaintains Overweight -> Overweight
2025-09-24NeedhamMaintains Buy -> Buy
2025-09-11TD CowenMaintains Buy -> Buy
2025-09-09UBSMaintains Buy -> Buy
2025-08-08UBSMaintains Buy -> Buy
2025-08-07MizuhoMaintains Neutral -> Neutral

Next Earnings Forecast Details

Next Earnings Details

Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate$0.08
Revenue Estimate288.67M
Revenue Q2Q18.15%
EPS Q2Q-28.94%
Number of Analysts21

Next Earnings Revisions

Revenue (1 Month)
-0.27%
Revenue (3 Months)
-0.25%
EPS (1 Month)
-2.73%
EPS (3 Months)
-13.14%

Next Earnings Summary

ACAD is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is 0.08 USD and the consensus revenue estimate is 288.67M USD.
The next earnings revenue estimate has been revised downward by 0.25% in the past 3 months.
 → Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ACAD revenue by date.ACAD revenue by date.
-2.445M
-97.38%		-804K
67.12%		1.072B
133,371.77%		1.27B
18.52%		1.414B
11.34%		1.604B
13.44%		1.7B
5.99%		1.873B
10.18%		2.187B
16.76%		2.264B
3.52%		2.105B
-7.02%
EBITDA
YoY % growth
ACAD ebitda by date.ACAD ebitda by date.
2.63M
785.52%		14.387M
447.03%		116.571M
710.25%		100.88M
-13.46%		197.01M
95.29%		414.3M
110.29%		502.3M
21.24%		698.49M
39.06%		1.243B
77.96%		1.624B
30.65%		1.274B
-21.55%
EBIT
YoY % growth
ACAD ebit by date.ACAD ebit by date.
-2.922M
-68.61%		-1.496M
48.80%		104.811M
7,106.08%		143.19M
36.62%		220.19M
53.77%		338.33M
53.65%		436.41M
28.99%		617.49M
41.49%		814.93M
31.97%		881.89M
8.22%		716.87M
-18.71%
Operating Margin
ACAD operating margin by date.ACAD operating margin by date.
119.51%186.07%9.78%11.27%15.57%21.09%25.67%32.97%37.26%38.95%34.06%
EPS
YoY % growth
ACAD eps by date.ACAD eps by date.
-0.38
60.82%		0.48
226.32%		2.29
377.08%		0.51
-77.91%		1.00
96.82%		1.77
77.51%		2.37
34.02%		3.15
33.16%		3.91
24.03%		4.98
27.38%		4.12
-17.30%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		0.08
-28.94%		0.13
-15.96%		0.22
-48.51%		0.23
-85.34%
Revenue
Q2Q % growth		288.67M
18.15%		310.6M
17.40%		331.11M
18.83%		351.39M
23.73%
EBITDA
Q2Q % growth		5.866M
-73.63%		23.413M
-38.81%		36.988M
-17.05%		42.024M
44.16%
EBIT
Q2Q % growth		4.927M
-74.46%		17.42M
-46.19%		46.048M
28.78%		56.355M
224.05%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 500M 1B 1.5B 2B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-8.28%
EPS Next 5 Year
6.61%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
13.33%
Revenue Next 5 Year
11.19%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
55.06%
EBIT Next 5 Year
44.44%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ACADIA PHARMACEUTICALS INC / ACAD Forecast FAQ

What is the price target for ACAD stock?

27 analysts have analysed ACAD and the average price target is 32.16 USD. This implies a price increase of 37.95% is expected in the next year compared to the current price of 23.31.


When does ACADIA PHARMACEUTICALS INC (ACAD) report earnings?

ACADIA PHARMACEUTICALS INC (ACAD) will report earnings on 2026-05-05.


Can you provide the consensus estimates for ACADIA PHARMACEUTICALS INC next earnings?

The consensus EPS estimate for the next earnings of ACADIA PHARMACEUTICALS INC (ACAD) is 0.08 USD and the consensus revenue estimate is 288.67M USD.


How many analysts cover ACADIA PHARMACEUTICALS INC (ACAD) stock?

The number of analysts covering ACADIA PHARMACEUTICALS INC (ACAD) is 27.